Thesis

KORU Medical Systems hit operating cash flow positive for the first time in FY2025. Revenue grew 22% to $41.1M while operating expenses grew 3%. The market hasn't noticed — or can't, because medtech sector rotation (XHE RSI 21, IHI RSI 21) is dragging everything down indiscriminately.

At $4.31, the market prices KRMD like a coin flip between survival and decline: roughly 53% bear, 42% base, 5% bull. That distribution doesn't match a company that just crossed cash flow breakeven, grew international revenue 80%, and has zero debt on a clean balance sheet.

The mispricing is specific: the market assigns 53% probability to a bear outcome for a company showing the opposite trajectory. Our read is 25% bull / 50% base / 25% bear. The $1.20/share probability edge (28% of current price) is concentrated in two disagreements — bull is 5x more likely than priced, bear is half as likely.

This is not a screaming buy today. Idiosyncratic variance is only 58.8% (below the 75% target), which means 41% of the stock's movement is sector and market noise. In a falling medtech sector, being right on the company and wrong on the sector is a real risk. But the setup is building toward something actionable.

The Business

KRMD makes the FREEDOM Infusion System — mechanical syringe drivers and needle sets for subcutaneous infusion of large-volume drugs, primarily immunoglobulin (SCIg). They're the US market leader in SCIg device delivery. 73 employees, Mahwah NJ, $191M enterprise value.

Three revenue streams: domestic core ($28M, +11%), international core ($10.9M, +80%), and pharma services/clinical trials ($2.3M, -6%). The international number is the headline, but the real story is what's happening underneath it.

What the 10-K Actually Shows

Operating leverage is the core signal. Revenue grew $7.5M. Total operating expenses grew $0.8M. That's 10.5 cents of incremental cost per dollar of incremental revenue. SG&A as a percentage of revenue dropped from 64.3% to 56.9%. At ≈$45-50M revenue run rate, the company crosses operating breakeven. They're at $41.1M and growing 20%+.

Operating cash flow turned positive at +$0.5M, up from ($0.3M). Stock-based comp is $2.7M, so cash earnings are still negative on an adjusted basis — but the direction is unambiguous. This is a phase transition from "burning cash with a story" to "approaching self-funding growth."

International growth is real but partially sector. We corroborated across the Big 3 immunoglobulin manufacturers: Grifols SCIg grew 66%, CSL Hizentra +16%, Takeda Ig +11.9%. The SCIg market is growing 7.6-13.7% CAGR. KRMD's 80% outpaces all of them — but off a small $10.9M base. Base effect inflates the percentage. Roughly 60% of the international growth story is sector tailwind, 40% is company-specific execution in new geographies.

Gross margin went the wrong direction. Down 110bps to 62.3%. Two causes: 15% tariff on Nicaragua-manufactured consumables (Command Medical, their primary subcontractor) and geographic mix shift toward lower-ASP international sales. The tariff is under Section 122 of the Trade Act — temporary, 150-day window, expiring approximately July 24, 2026. If it expires without renewal, margin headwind reverses. If replaced by alternative authority, the problem persists.

Balance sheet is clean. $8.9M cash, zero drawn on $10M HSBC credit facility, 2.44x current ratio, 1.84x quick ratio against 1.25x covenant. No going concern, no material weakness, no auditor change, no litigation. Accumulated deficit of $32M tells you this company has been losing money for a long time — the inflection is new.

Management upgraded for commercialization. New CTO Eric Schiller (December 2025, ex-Sanofi, led 80+ pipeline assets in drug-device development) and new CCO Adam Kalbermatten (July 2025, ex-BD Drug Delivery GM). These are people who left large medtech platforms for a 73-person company. That's personal conviction.

Next-gen pump signal in the CapEx. FY2025 capital expenditures were $0.9M for "manufacturing equipment related to our production line for our next generation consumables AND infusion pumps." Prior year said consumables only. Addition of "infusion pumps" means a next-gen pump has progressed to production tooling. No timeline disclosed.

What the Market Sees vs What We See

The factor decomposition reveals why the stock is falling despite improving fundamentals. KRMD has a beta of 0.50 to SPY and meaningful exposure to the medtech sector. XHE and IHI are both at RSI 21 — deeply oversold. KRMD's 35% drawdown from its $6.61 52-week high is partly company, mostly sector. At RSI 34, it's actually outperforming the sector selloff.

This creates a dual-catalyst setup: if medtech recovers AND operating inflection confirms, KRMD gets both a sector bounce and a fundamental re-rating. The convergence is where the magnitude lives. But with 58.8% idiosyncratic variance, you're taking 41% sector risk you have no edge in.

Valuation math: FY2026E revenue of ≈$48.5M (domestic +10%, international +40%, pharma flat). At 5x forward EV/Sales — standard for a 62% gross margin medtech growing 15-20% near breakeven — fair value is $5.50-5.65/share. KRMD trades at 3.9x forward, a 22-24% discount. It's priced like a struggling company, not an inflecting one.

The Bear Case

Gross margin could keep compressing. If Section 122 tariff is replaced by permanent authority, and international mix continues shifting toward lower-ASP markets, 62.3% could become 60% or lower. That delays breakeven and narrows the operating leverage story.

EU MDR compliance is a binary risk. International revenue ($10.9M, growing 80%) requires CE certification under the EU Medical Device Regulation by December 2028. Compliance cost is undisclosed. If KRMD fails to comply, they lose access to their fastest-growing segment entirely.

Enable Injections is a credible competitive threat. Sanofi invested $30M in January 2026 to accelerate manufacturing of Enable's enFuse on-body device — an electronic, wearable SC infusion system delivering 5-50mL. FDA combination product approval (2023), EU MDR CE Mark (March 2025), Incyte partnership (October 2025). Enable currently targets pharma drug-device combinations, not standalone Ig infusion. But if they pivot to KRMD's core market, the threat is real.

The 170+ pipeline number overstates KRMD's addressable market. A peer-reviewed study (PMC11407384) identified 182 large-volume SC products, 151 in development. But most use concentrated injections or proprietary on-body devices, not pump-based infusion. Halozyme's ENHANZE platform — royalty revenue +51% in Q4 2025 — actually works against KRMD by concentrating drugs to volumes small enough for single-site injection, eliminating the need for a pump.

R&D step-up is coming. R&D declined 16.6% in FY2025 during the CTO transition. With a new CTO from Sanofi's device group, R&D spending will increase in FY2026. This partially offsets the SG&A leverage and could push breakeven to FY2027.

The Bull Case

Operating leverage is durable and genuinely idiosyncratic. Cross-ticker corroboration confirmed this is NOT a sector trend. Small-cap medtech companies broadly are not showing revenue +22% / OpEx +3%. KRMD's fixed cost structure is in place (field sales, EU commercial team) and each incremental dollar of revenue drops ≈$0.57 to gross profit. This is company-specific execution.

West Pharmaceutical exited. WST announced the sale of its SmartDose on-body injector platform in February 2026, citing manufacturing economics challenges. A competitor left the field. That validates KRMD's niche and reduces near-term competitive pressure.

Term loan decision creates an information event. The $5M HSBC term loan draw window expires March 31, 2026. If KRMD doesn't draw, that's a self-funding signal — management saying they don't need external capital. Watch for the 8-K.

Sector mean reversion. XHE and IHI at RSI 21 are at extreme oversold levels. Statistical mean reversion probability is high, though timing is unknowable. When medtech bounces, KRMD bounces with it — plus the company-specific re-rating.

Forward Expected Value

Upside/downside asymmetry: 2.8:1. Bull scenario requires international growth sustaining +40-50%, operating breakeven achieved, and next-gen pump disclosed. Base requires revenue ≈$48M with margins stable. Bear requires growth deceleration, margin compression, and continued sector drag.

Factor-adjusted alpha: 6.6% at current conviction (50%), rising to 9.3% if key gaps are filled and conviction reaches 70%. Modest but real. Within the 5-15% realistic range for orthogonal alpha.

Entry Framework

Phase the entry around catalysts. With 58.8% idio, going all-in risks being right on the company and wrong on the sector.

Cost of waiting: ≈5% in expected return for ≈50% reduction in thesis risk. That's a good trade at 50% conviction.

What Breaks the Thesis

• International growth below +20% in FY2026 (demand deceleration, not just base effect)
• Gross margin below 59% (tariff expansion + mix shift overwhelming leverage)
• Enable Injections wins an Ig infusion contract (direct competitive displacement)
• EU MDR compliance costs disclosed at >$5M (material cash drain)
• Insider selling at current levels (management doesn't believe the inflection)

What Confirms It

• Term loan not drawn (self-funding signal)
• Q1 international >35% with GM >61% (trajectory confirmed)
• Insider buying at $4.31 (conviction with personal capital)
• Section 122 tariff expires July 2026 (margin headwind removed)
• Next-gen pump partnership or disclosure (product catalyst)

LR Signal: 1.5

Mild bullish divergence from market pricing. The operating inflection is real, primary-source verified, and corroborated as genuinely idiosyncratic. The market is overweighting the bear case (53% vs our 25%) for a company that just hit OCF positive. But 58.8% idio variance limits position purity, and the sector headwind is real and unhedged. The edge exists but isn't extreme — this is a building setup, not a forced entry.

Evidence